⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 34 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 5 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 34 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 5 hours ago
🛡️ EUSW
🇬🇧
💊

Adstiladrin

nadofaragene firadenovec
Non-Muscle Invasive Bladder Neoplasms
✅ Authorised Advanced therapy
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.

⚠️ Patient safety

No

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.